Mankind Pharma Limited — Board Meeting, 23-01-2025: Outcome of Board Meeting

The Board of Directors has approved the unaudited standalone and consolidated financial results for the quarter and nine months ending December 31, 2024. Key highlights include total income of ₹7,599.98 Crore and profit after tax from continuing operations at ₹416.38 Crore. The company has completed the acquisition of Bharat Serums and Vaccines Limited for ₹13,768 Crore. Mankind Pharma also raised funds through the issuance of ₹5,000 Crore in secured, redeemable non-convertible debentures and ₹3,000 Crore through a qualified institutional placement.